The recent insider selling at Pediatrix Medical Group, combined with the relatively low insider ownership, raises caution. The lack of insider buying over the past year also adds to this caution. The company is not considered a rush to buy.
Pediatrix Medical Group's low P/E ratio may be due to expectations of falling earnings. The outlook for shrinking earnings contributes to its low P/E, acting as a barrier for the share price unless conditions improve.
The insider transactions at Pediatrix Medical Group lack confidence. The level of insider ownership is also not notably high. Potential investors should be aware of the associated risks.
Pediatrix Medical Group's ROCE trend reflects low reinvestment and stagnant returns, possibly contributing to a steep stock price drop. Better investments might be elsewhere.
The unchanged market sentiment towards Pediatrix Medical Group over the past year may suggest persistent challenges. Coupled with an annualized loss surpassing 11% in half a decade, it may not be a promising stock to buy.
Given the lower PE ratio and expected earnings surge, it might be a good time to increase or initiate holdings in Pediatrix Medical Group. The bullish future profit prospects aren't fully reflected in the current share price. Investors should also consider the management's past performance and capital structure before deciding to invest.
Pediatrix Medical股票討論區
2023Q1營收增長1.8%,營業利潤大幅下滑25.9%,由於特殊費用減少,淨利潤反而大幅增長。
目前17倍市盈率,市盈率TTM已經降到了11倍,考慮到目前的增長是特殊費用波動造成的,並非核心盈利能力的改善,可以多觀察幾個季度。
暫無評論